Articles producció científica> Medicina i Cirurgia

Dyslipemias and pregnancy, an update

  • Dades identificatives

    Identificador: imarina:9138974
    Autors:
    Mauri MCalmarza PIbarretxe D
    Resum:
    © 2020 The Authors During pregnancy there is a physiological increase in total cholesterol (TC) and triglycerides (TG) plasma concentrations, due to increased insulin resistance, oestrogens, progesterone, and placental lactogen, although their reference values are not exactly known, TG levels can increase up to 300 mg/dL, and TC can go as high as 350 mg/dL. When the cholesterol concentration exceeds the 95th percentile (familial hypercholesterolaemia (FH) and transient maternal hypercholesterolaemia), there is a predisposition to oxidative stress in foetal vessels, exposing the newborn to a greater fatty streaks formation and a higher risk of atherosclerosis. However, the current treatment of pregnant women with hyperlipidaemia consists of a diet and suspension of lipid-lowering drugs. The most prevalent maternal hypertriglyceridaemia (HTG) is due to secondary causes, like diabetes, obesity, drugs, etc. The case of severe HTG due to genetic causes is less prevalent, and can be a higher risk of maternal-foetal complications, such as, acute pancreatitis (AP), pre-eclampsia, preterm labour, and gestational diabetes. Severe HTG-AP is a rare but potentially lethal pregnancy complication, for the mother and the foetus, usually occurs during the third trimester or in the immediate postpartum period, and there are no specific protocols for its diagnosis and treatment. In conclusion, it is crucial that dyslipidaemia during pregnancy must be carefully evaluated, not just because of the acute complications, but also because of the future cardiovascular morbidity and mortality of the newborn child. That is why the establishment of consensus protocols or guidelines is essential for its management.
  • Altres:

    Autor segons l'article: Mauri M; Calmarza P; Ibarretxe D
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Ibarretxe Gerediaga, Daiana
    Paraules clau: Severe hypertriglyceridemia Pregnancy Plasma-lipids Maternal hypercholesterolemia Low-density-lipoprotein Lipid profile Lipase gene Hypertriglyceridaemia Hypercholesterolaemia Homozygous familial hypercholesterolemia Familial hypercholesterolaemia Endothelial function Cardiovascular-disease Acute-pancreatitis Acute pancreatitis
    Resum: © 2020 The Authors During pregnancy there is a physiological increase in total cholesterol (TC) and triglycerides (TG) plasma concentrations, due to increased insulin resistance, oestrogens, progesterone, and placental lactogen, although their reference values are not exactly known, TG levels can increase up to 300 mg/dL, and TC can go as high as 350 mg/dL. When the cholesterol concentration exceeds the 95th percentile (familial hypercholesterolaemia (FH) and transient maternal hypercholesterolaemia), there is a predisposition to oxidative stress in foetal vessels, exposing the newborn to a greater fatty streaks formation and a higher risk of atherosclerosis. However, the current treatment of pregnant women with hyperlipidaemia consists of a diet and suspension of lipid-lowering drugs. The most prevalent maternal hypertriglyceridaemia (HTG) is due to secondary causes, like diabetes, obesity, drugs, etc. The case of severe HTG due to genetic causes is less prevalent, and can be a higher risk of maternal-foetal complications, such as, acute pancreatitis (AP), pre-eclampsia, preterm labour, and gestational diabetes. Severe HTG-AP is a rare but potentially lethal pregnancy complication, for the mother and the foetus, usually occurs during the third trimester or in the immediate postpartum period, and there are no specific protocols for its diagnosis and treatment. In conclusion, it is crucial that dyslipidaemia during pregnancy must be carefully evaluated, not just because of the acute complications, but also because of the future cardiovascular morbidity and mortality of the newborn child. That is why the establishment of consensus protocols or guidelines is essential for its management.
    Àrees temàtiques: Pharmacology (medical) Peripheral vascular disease Medicina iii Medicina i Cardiology and cardiovascular medicine
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat
    Data d'alta del registre: 2024-07-27
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.sciencedirect.com/science/article/pii/S0214916820301066?via%3Dihub
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Clinica E Investigacion En Arteriosclerosis. 33 (1): 41-52
    Referència de l'ítem segons les normes APA: Mauri M; Calmarza P; Ibarretxe D (2021). Dyslipemias and pregnancy, an update. Clinica E Investigacion En Arteriosclerosis, 33(1), 41-52. DOI: 10.1016/j.arteri.2020.10.002
    DOI de l'article: 10.1016/j.arteri.2020.10.002
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2021
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cardiology and Cardiovascular Medicine,Peripheral Vascular Disease,Pharmacology (Medical)
    Severe hypertriglyceridemia
    Pregnancy
    Plasma-lipids
    Maternal hypercholesterolemia
    Low-density-lipoprotein
    Lipid profile
    Lipase gene
    Hypertriglyceridaemia
    Hypercholesterolaemia
    Homozygous familial hypercholesterolemia
    Familial hypercholesterolaemia
    Endothelial function
    Cardiovascular-disease
    Acute-pancreatitis
    Acute pancreatitis
    Pharmacology (medical)
    Peripheral vascular disease
    Medicina iii
    Medicina i
    Cardiology and cardiovascular medicine
  • Documents:

  • Cerca a google

    Search to google scholar